Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China
· Delayed Price · Currency is CNY 64.05
+2.05 (3.31%)
Mar 10, 2026, 3:00 PM CST
SHA:688621 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 1,218 | 1,077 | 930.98 | 676.39 | 492.86 | Upgrade
|
| Other Revenue | - | 1.61 | 1.14 | 0.21 | 0.79 | Upgrade
|
| Revenue | 1,218 | 1,078 | 932.12 | 676.61 | 493.65 | Upgrade
|
| Revenue Growth (YoY) | 12.92% | 15.70% | 37.76% | 37.06% | 42.12% | Upgrade
|
| Cost of Revenue | - | 537.33 | 403.77 | 301.15 | 229.97 | Upgrade
|
| Gross Profit | 1,218 | 541.14 | 528.35 | 375.46 | 263.68 | Upgrade
|
| Selling, General & Admin | - | 150.44 | 153.24 | 110.81 | 85.63 | Upgrade
|
| Research & Development | - | 171.94 | 123.68 | 89.69 | 47.58 | Upgrade
|
| Other Operating Expenses | 1,014 | 0.76 | 0.2 | 0.16 | 0.04 | Upgrade
|
| Operating Expenses | 1,014 | 364.82 | 334.89 | 219.32 | 143.72 | Upgrade
|
| Operating Income | 204.2 | 176.32 | 193.46 | 156.14 | 119.97 | Upgrade
|
| Interest Expense | - | -16.11 | -12.18 | -9.7 | -3.56 | Upgrade
|
| Interest & Investment Income | - | 5.67 | 8.53 | 8.78 | 2.52 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.12 | -2.66 | -2.47 | -0.96 | -0.72 | Upgrade
|
| EBT Excluding Unusual Items | 201.08 | 163.22 | 187.35 | 154.25 | 118.21 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -1.82 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.31 | -0.71 | -0.25 | -0.51 | Upgrade
|
| Other Unusual Items | - | 14.9 | 6.76 | 15.14 | 4.4 | Upgrade
|
| Pretax Income | 201.08 | 175.99 | 193.4 | 169.14 | 122.1 | Upgrade
|
| Income Tax Expense | 5 | 6.97 | 10.5 | 10.43 | 13.31 | Upgrade
|
| Earnings From Continuing Operations | 196.08 | 169.01 | 182.9 | 158.7 | 108.79 | Upgrade
|
| Minority Interest in Earnings | - | 8.4 | 1.86 | -2.23 | -3.13 | Upgrade
|
| Net Income | 196.08 | 177.41 | 184.76 | 156.47 | 105.66 | Upgrade
|
| Net Income to Common | 196.08 | 177.41 | 184.76 | 156.47 | 105.66 | Upgrade
|
| Net Income Growth | 10.53% | -3.98% | 18.08% | 48.09% | 45.81% | Upgrade
|
| Shares Outstanding (Basic) | 110 | 112 | 112 | 112 | 98 | Upgrade
|
| Shares Outstanding (Diluted) | 110 | 112 | 112 | 112 | 98 | Upgrade
|
| Shares Change (YoY) | -2.44% | 0.28% | 0.19% | 14.09% | 16.84% | Upgrade
|
| EPS (Basic) | 1.79 | 1.58 | 1.65 | 1.40 | 1.08 | Upgrade
|
| EPS (Diluted) | 1.79 | 1.58 | 1.65 | 1.40 | 1.08 | Upgrade
|
| EPS Growth | 13.29% | -4.24% | 17.86% | 29.80% | 24.80% | Upgrade
|
| Free Cash Flow | - | 1.54 | 19.9 | 0.09 | 3.29 | Upgrade
|
| Free Cash Flow Per Share | - | 0.01 | 0.18 | 0.00 | 0.03 | Upgrade
|
| Dividend Per Share | - | 0.163 | 0.165 | 0.429 | 0.189 | Upgrade
|
| Dividend Growth | - | -1.21% | -61.50% | 126.41% | - | Upgrade
|
| Gross Margin | 100.00% | 50.18% | 56.68% | 55.49% | 53.41% | Upgrade
|
| Operating Margin | 16.77% | 16.35% | 20.76% | 23.08% | 24.30% | Upgrade
|
| Profit Margin | 16.10% | 16.45% | 19.82% | 23.13% | 21.40% | Upgrade
|
| Free Cash Flow Margin | - | 0.14% | 2.14% | 0.01% | 0.67% | Upgrade
|
| EBITDA | 231.27 | 201.69 | 215.47 | 173.19 | 131.47 | Upgrade
|
| EBITDA Margin | 18.99% | 18.70% | 23.12% | 25.60% | 26.63% | Upgrade
|
| D&A For EBITDA | 27.07 | 25.38 | 22.01 | 17.05 | 11.5 | Upgrade
|
| EBIT | 204.2 | 176.32 | 193.46 | 156.14 | 119.97 | Upgrade
|
| EBIT Margin | 16.77% | 16.35% | 20.76% | 23.08% | 24.30% | Upgrade
|
| Effective Tax Rate | 2.48% | 3.96% | 5.43% | 6.17% | 10.90% | Upgrade
|
| Revenue as Reported | - | 1,078 | 932.12 | 676.61 | 493.65 | Upgrade
|
| Advertising Expenses | - | 0.58 | 1.69 | 1.17 | 1.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.